Page 5 - Pharmaceutical Development News Today

Shares of SWK Holdings Co. (NASDAQ:SWKH – Get Rating) were down 0.2% during mid-day trading on Tuesday . The company traded as low as $17.41 and last traded at $17.46. Approximately 4,745 shares changed hands during trading, a decline of 59% from the average daily volume of 11,569 shares. The stock had previously closed at […]

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Apr 16, 2023--

SWK (NASDAQ:SWKH – Get Rating) had its price target lowered by Maxim Group from $25.00 to $22.00 in a research note published on Tuesday morning, The Fly reports. The firm currently has a buy rating on the stock. SWK Stock Down 0.1 % Shares of NASDAQ:SWKH opened at $17.50 on Tuesday. SWK has a 12 […]

SWK (NASDAQ:SWKH – Get Rating) had its target price decreased by Maxim Group from $25.00 to $22.00 in a research report report published on Tuesday, The Fly reports. Maxim Group currently has a buy rating on the stock. SWK Stock Down 0.1 % Shares of NASDAQ:SWKH opened at $17.50 on Tuesday. The firm’s 50 day […]

Seda are honoured to have been named winners of the Business Growth Award at the prestigious Bionow Awards 2022. This award recognises our outstanding growth, innovation, and contribution to the North of England’s life sciences sector, as well as our commitment to innovation and excellence in the pharmaceutical industry.

Conference Call and Live Audio Webcast Scheduled for Today, April 3, 2023, at 10:00 a.m. ET Corporate Highlights Jody Staggs named President and Chief...

SWK (NASDAQ:SWKH – Get Rating) is set to announce its earnings results on Monday, March 27th. SWK Price Performance Shares of NASDAQ:SWKH opened at $17.88 on Friday. SWK has a 1 year low of $16.06 and a 1 year high of $19.99. The stock has a market capitalization of $229.22 million, a price-to-earnings ratio of […]

Signed exclusive worldwide license for pan-RAF inhibitor naporafenib and completed concurrent $100 million equity offering Multiple clinical data readouts planned in 2023, including for HERKULES-2,... | March 23, 2023

Signed exclusive worldwide license for pan-RAF inhibitor naporafenib and completed concurrent $100 million equity offering Multiple clinical data readouts planned in 2023, including for HERKULES-2, HERKULES-3, FLAGSHP-1, and THUNDERBBOLT-1 trials ...

/PRNewswire/ -- The "Process Validation Guidance Requirements course (FDA and EU Annex 15: Qualifications and Validation) Workshop" training has been added to...